APA

Jacobs L. D., Cookfair D. L., Rudick R. A., Herndon R. M., Richert J. R., Salazar A. M., Fischer J. S., Goodkin D. E., Granger C. V. & Simon J. H. (19971114). A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). : Multiple sclerosis (Houndmills, Basingstoke, England).

Chicago

Jacobs L D, Cookfair D L, Rudick R A, Herndon R M, Richert J R, Salazar A M, Fischer J S, Goodkin D E, Granger C V and Simon J H. 19971114. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). : Multiple sclerosis (Houndmills, Basingstoke, England).

Harvard

Jacobs L. D., Cookfair D. L., Rudick R. A., Herndon R. M., Richert J. R., Salazar A. M., Fischer J. S., Goodkin D. E., Granger C. V. and Simon J. H. (19971114). A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). : Multiple sclerosis (Houndmills, Basingstoke, England).

MLA

Jacobs L D, Cookfair D L, Rudick R A, Herndon R M, Richert J R, Salazar A M, Fischer J S, Goodkin D E, Granger C V and Simon J H. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). : Multiple sclerosis (Houndmills, Basingstoke, England). 19971114.